Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) announced on Tuesday that it has received US Food and Drug Administration (FDA) clearance for a clinical trial of its TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for treating moderate-to-severe atopic dermatitis (AD).
ICP-332 demonstrated positive results in a prior China Phase II study, showing better efficacy than other AD treatments. The drug targets the JAK-STAT signalling pathway, crucial in AD development.
At present, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.
Biophytis advances sarcopenia treatment with positive Phase 2 results
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
BioSurfaces collaborates with Morphocell Technologies
iOncologi acquires TargImmune Therapeutics
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
Korro Bio receives FDA orphan drug designation for KRRO-110
SpliceBio doses first patient in Phase 1/2 ASTRA study of SB-007
Third Arc Bio reports first patient dosed in first-in-human study assessing ARC101
Amgen reports positive Phase 3 trial results for UPLIZNA in generalised myasthenia gravis
Celltrion launches STELARA biosimilar STEQEYMA in US market
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India